Holen Sie sich die Stockscreener-App
103.43
0.14%
0.14
Schlusskurs vom Vortag:
$103.29
Offen:
$103.3
24-Stunden-Volumen:
2.71M
Relative Volume:
0.54
Marktkapitalisierung:
$19.74B
Einnahmen:
$3.08B
Nettoeinkommen (Verlust:
$-986.58M
KGV:
-19.45
EPS:
-5.3172
Netto-Cashflow:
$292.08M
1W Leistung:
+0.18%
1M Leistung:
+1.06%
6M Leistung:
+120.06%
1J Leistung:
+108.91%
1-Tages-Spanne:
$103.19
$103.50
1-Wochen-Bereich:
$103.14
$103.50
52-Wochen-Spanne:
$38.81
$103.54
Exact Sciences Corp Stock (EXAS) Company Profile
Firmenname
Exact Sciences Corp
Sektor
Branche
Telefon
608-284-5700
Adresse
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
103.43 | 19.72B | 3.08B | -986.58M | 292.08M | -5.3172 |
|
TMO
Thermo Fisher Scientific Inc
|
510.93 | 193.53B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
209.50 | 149.33B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
635.66 | 50.36B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
122.90 | 35.73B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
333.33 | 32.24B | 3.17B | 642.63M | 539.81M | 10.77 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-20 | Herabstufung | Mizuho | Outperform → Neutral |
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-01-02 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-08-02 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Hochstufung | Craig Hallum | Hold → Buy |
| 2023-05-05 | Eingeleitet | UBS | Neutral |
| 2023-03-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-02-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-03 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Bestätigt | BTIG Research | Buy |
| 2021-07-29 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-29 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-29 | Bestätigt | Stifel | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Strong Buy |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-29 | Herabstufung | UBS | Buy → Neutral |
| 2020-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-02 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-10 | Fortgesetzt | BTIG Research | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Dougherty & Company | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-17 | Bestätigt | BofA/Merrill | Buy |
| 2019-10-01 | Fortgesetzt | Craig Hallum | Buy |
| 2019-09-26 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-26 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-09-05 | Fortgesetzt | The Benchmark Company | Hold |
| 2018-08-13 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-01-29 | Eingeleitet | Goldman | Neutral |
| 2018-01-08 | Bestätigt | The Benchmark Company | Buy |
| 2017-11-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Herabstufung | BTIG Research | Buy → Neutral |
Alle ansehen
Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten
Exact Sciences shareholders approve merger with Abbott Laboratories By Investing.com - Investing.com Nigeria
Exact Sciences (EXAS) Shareholders Approve Abbott Acquisition - GuruFocus
Exact Sciences shareholders approve merger with Abbott Laboratories - Investing.com
Exact Sciences stockholders approve acquisition by Abbott - marketscreener.com
Exact Sciences shareholders approve Abbott acquisition - Investing.com
Exact Sciences Shareholders Approve Acquisition by Abbott Laboratories - marketscreener.com
Exact Sciences shareholders approve $105 per share Abbott acquisition - StreetInsider
Exact Sciences Stockholders Approve Acquisition by Abbott - Business Wire
Exact Sciences Corp.: The Quiet Cancer-Test Stock Everyone’s Watching - AD HOC NEWS
Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up - The Globe and Mail
Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock - Yahoo Finance
Aberdeen Group plc Increases Stock Position in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Corporation $EXAS is Eagle Health Investments LP's 10th Largest Position - MarketBeat
Assessing Exact Sciences (EXAS) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
How The Abbott Offer Is Rewriting The Story For Exact Sciences (EXAS) - Yahoo Finance
How Investors May Respond To Exact Sciences (EXAS) Narrowing Losses And Oncotype DX Milestone - Yahoo Finance
Exact Sciences (EXAS) Climbs to 2-Year High on Abbot Merger Reports - MSN
Exact Sciences Faces Rising Operational Risk and Strategic Constraints Amid Pending Abbott Merger - The Globe and Mail
Key facts: Exact Sciences to merge with Abbott by Q2 2026; 2025 revenue up 18% - TradingView
Exact Sciences misses Q4 expectations for earnings, beats for revenue - Wisconsin State Journal
Illinois Municipal Retirement Fund Boosts Stake in Exact Sciences Corporation $EXAS - MarketBeat
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight - GuruFocus
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Exact Sciences: Fourth Quarter Earnings Overview - bitget.com
Exact Sciences: Q4 Earnings Snapshot - kens5.com
Exact Sciences (EXAS) Surpasses Q4 Revenue Expectations - GuruFocus
Exact Sciences Q4 Loss Narrows, Revenue Rises - marketscreener.com
EXACT SCIENCES CORP SEC 10-K Report - TradingView
Exact Sciences Corp. Reports Record Fourth Quarter and Full Year 2025 Results - TradingView
Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results - Business Wire
Is It Too Late To Consider Exact Sciences (EXAS) After The US$105 Abbott Offer - Yahoo Finance
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 - GlobeNewswire Inc.
Alger Mid Cap 40 ETF Q4 2025 Portfolio Update - Seeking Alpha
Exact Sciences Corporation (NASDAQ:EXAS) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Take Profit: Will Exact Sciences Corporation benefit from green energy policiesLayoff News & Technical Buy Zone Confirmation - baoquankhu1.vn
Aug PreEarnings: Will Exact Sciences Corporation outperform its industry peersQuarterly Market Summary & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Allianz Asset Management GmbH Makes New Investment in Exact Sciences Corporation $EXAS - MarketBeat
Biotech operator Personalis sees 10% spike from Medicare covering lung cancer blood test - Mugglehead Magazine
Exact Sciences (NASDAQ:EXAS) Sets New 12-Month HighTime to Buy? - MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Northfield Bancorp Inc. (NasdaqNFBK), Coterra Energy Inc. (NYSECTRA), Exact Sciences Corporation (Nasdaq – EXAS), Semrush Holdings, Inc. (NYSE – - ChartMill
Exact Sciences (EXAS): Buy, Sell, or Hold Post Q3 Earnings? - Yahoo Finance
Abbott to Buy Cancer-Screener Exact Sciences for $21 Billion - MSN
Exact Sciences Milestone In Breast Cancer Genomics And What It Means For EXAS - Yahoo Finance
PTAB Tosses 2nd Patent On Cologuard Colon Cancer Test - Law360
Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences’ ’746 Patent - The AI Journal
Exact Sciences (EXAS) Advances as HSR Period Expires for Abbott Deal - GuruFocus
The Truth About Exact Sciences Corp: Is This Cancer-Test Stock Quietly Going Viral or About to Flop? - AD HOC NEWS
Principal Financial Group Inc. Grows Position in Exact Sciences Corporation $EXAS - MarketBeat
C WorldWide Group Holding A S Has $46.97 Million Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Corporation $EXAS Shares Sold by Heritage Investors Management Corp - MarketBeat
Medicare coverage pathway established for multi-cancer detection tests By Investing.com - Investing.com Nigeria
Finanzdaten der Exact Sciences Corp-Aktie (EXAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.01%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):